Last reviewed · How we verify

TJO-018 (HA 0.15%) — Competitive Intelligence Brief

TJO-018 (HA 0.15%) (TJO-018 (HA 0.15%)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Artificial tear / Ocular lubricant. Area: Ophthalmology.

marketed Artificial tear / Ocular lubricant Ocular surface (non-receptor mediated) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

TJO-018 (HA 0.15%) (TJO-018 (HA 0.15%)) — Taejoon Pharmaceutical Co., Ltd.. TJO-018 is a hyaluronic acid-based topical formulation that provides lubrication and moisture retention to the ocular surface.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TJO-018 (HA 0.15%) TARGET TJO-018 (HA 0.15%) Taejoon Pharmaceutical Co., Ltd. marketed Artificial tear / Ocular lubricant Ocular surface (non-receptor mediated)
Meticel Ofteno® 0.5% Meticel Ofteno® 0.5% Laboratorios Sophia S.A de C.V. marketed Artificial tear / Ocular lubricant
Systane Complete PF Systane Complete PF University of California, Berkeley marketed Artificial tear / Ocular lubricant
Sodium hyaluronate eye drops Sodium hyaluronate eye drops Guang'anmen Hospital of China Academy of Chinese Medical Sciences marketed Artificial tear / ocular lubricant
Ophthalmic Emulsion Ophthalmic Emulsion Allergan marketed Artificial tear / Ocular lubricant
Optive® Optive® Laboratorios Sophia S.A de C.V. marketed Artificial tear / Ocular lubricant
Systane Hydration PF Systane Hydration PF University of Alabama at Birmingham marketed Artificial tear / Ocular lubricant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Artificial tear / Ocular lubricant class)

  1. Laboratorios Sophia S.A de C.V. · 7 drugs in this class
  2. Allergan · 3 drugs in this class
  3. University of Waterloo · 2 drugs in this class
  4. University of California, Berkeley · 2 drugs in this class
  5. Bp Consulting, Inc · 1 drug in this class
  6. Chong Kun Dang Pharmaceutical · 1 drug in this class
  7. Clinica Oftamologica Zona Sul · 1 drug in this class
  8. Fundação Altino Ventura · 1 drug in this class
  9. Medical University of South Carolina · 1 drug in this class
  10. Ocuwize LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TJO-018 (HA 0.15%) — Competitive Intelligence Brief. https://druglandscape.com/ci/tjo-018-ha-0-15. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: